As members of the chemokine family, macrophage inflammatory protein 1 alpha (MIP-1a) and MIP-1b are unique in that they both consist of non-allelic isoforms encoded by different genes, namely chemokine (C-C motif) ligand 3 (CCL3), CCL4, CCL3-like 1 (CCL3L1) and CCL4L1. The products of these genes and of CCL5 (encoding RANTES, i.e., regulated on activation, normal T expressed and secreted) can block or interfere with human immunodeficiency virus type 1 (HIV-1) infection through competitive binding to chemokine (C-C motif) receptor 5 (CCR5). Our analyses of 411 adolescents confirmed that CCL3 and CCL4 genes occurred invariably as single copies (two per diploid genome), whereas the copy numbers of CCL3L1 and CCL4L1 varied extensively (0-11 and 1-6 copies, respectively). Neither CCL3L1 nor CCL4L1 gene copy number variation showed appreciable impact on susceptibility to or control of HIV-1 infection. Within individuals, linear correlation between CCL3L1 and CCL4L1 copy numbers was moderate regardless of ethnicity (Pearson correlation coefficients ¼ 0.63-0.65, Po0.0001), suggesting that the two loci are not always within the same segmental duplication unit. Persistently low serum MIP-1a and MIP-1b (in the pg/ml range) compared with high CCL5 concentration (ng/ml range) implied that multi-copy genes CCL3L1 and CCL4L1 conferred little advantage in the intensity of expression among uninfected or infected adolescents.
Introduction
Chemokines (chemotactic cytokines) are small, secreted molecules involved in immunological and inflammatory responses. More than 50 human chemokine receptors and ligands have been identified and classified into four major groups based on their conserved C-X-C (a), C-C (b), C (g), C-X3-C (d) motifs. [1] [2] [3] The importance of chemokines and their receptors in health and disease has been well documented, especially with the identification of allelic variants that differentially influence disease susceptibility and severity. [4] [5] [6] [7] In the context of human immunodeficiency virus type 1 (HIV-1) infection, members of the C-C and C-X-C chemokine subfamilies are of great interest (reviewed by Berger et al.; 4 Tang and Kaslow 6 and Lederman et al.
7
). More specifically the, chemokine (C-C motif) receptor 5 (CCR5) serves as the major coreceptor for primary HIV-1 isolates. Natural CCR5 ligands (chemokines), mostly CCL3/CCL3L1 (MIP-1a, i.e., macrophage inflammatory protein 1 alpha), CCL4/CCL4L1 (MIP-1b) and CCL5 (RANTES, i.e., regulated on activation, normal T expressed and secreted), can inhibit or reduce viral entry into CD4 þ T-cells through competitive binding to CCR5 or other indirect mechanisms. [8] [9] [10] [11] CCL3 and CCL4, located on the long arm of human chromosome 17, are both single-copy genes (two copies per diploid genome, Figure 1 ) regardless of population backgrounds, but the copy numbers of the neighboring CCL3-and CCL4-like genes CCL3L1 and CCL4L1 are highly variable owing to a hot spot for segmental duplication, [12] [13] [14] [15] [16] [17] with most individuals having 1-6 copies of CCL3L1 and CCL4L1. 14, 17 CCL3L1 gene dosage (copy number variation, CNV) has been reported to influence HIV-1 infection and pathogenesis. 17 More specifically, CCL3L1 copy numbers lower than the average for each ethnic group evaluated were associated with unfavorable outcomes, presumably due to lower expression of CCL3 (MIP-1a) and reduced capacity to block or interfere with HIV-1 binding to CCR5. 17 In addition, CCL3L1 gene dose and CCR5 genotypes appeared to have synergistic or interactive effects, being consistent with the notion that CCR5 genotypes also influence HIV/AIDS, often in a population-specific manner. 6, [18] [19] [20] These findings remain to be confirmed in other populations and settings. Thus, we have examined the relationships of CCL3L1 and CCL4L1 gene dose to gene expression and HIV-1-related outcomes in a racially diverse cohort of North American adolescents.
Results
Variable CCL3L1 and CCL4L1 gene copy number In quantitative 5 0 exonuclease (TaqMan) assays done for 184 HIV-1 seronegative (population control) and 227 HIV-1 seropositive adolescents (Table 1) , CCL3 and CCL4 were detected constantly at two copies per diploid genome, whereas CCL3L1 and CCL4L1 occurred with considerable variation in their copy number ( Figure 2 ).
The number of CCL3L1 copies ranged from zero (rarely) to 11 (also rare) per genome. African Americans had a greater number of CCL3L1 copies per genome: 55.8% of them had one to four and 44.2% had more than four. In the non-African American group (mainly Hispanic and European Americans), 58.0% had one to three copies and 41.2% had more than three ( Figure 2 ). The median copy number for CCL3L1 was four for African Americans and three for those grouped as others.
Similarly, the CCL4L1 copy number varied from one to six per diploid genome (Figure 2) . In African Americans, 74.1% had one to three copies, whereas 25.9% had more than three. The respective proportions among others were 87.8 and 12.2% (Po0.01 between the two groups).
The median number of CCL4L1 copies was three for African Americans and two for those grouped as others. Regardless of ethnicity, CCL3L1 and CCL4L1 gene copies showed a moderately strong overall linear correlation (Pearson correlation coefficients r ¼ 0.63-0.65, Po0.0001). However, at the individual level, CCL3L1 gene duplication was more frequent than CCL4L1, especially when the number of CCL3L1 genes exceeded three copies per genome.
Testing of six chimpanzee (Pan troglodytes) samples with the same TaqMan assay detected CCL3 in none and CCL3L1 in all of them, with numbers of the latter gene ranging from 9 to 13. Similar findings were also reported by others.
17
CCL3L1 and CCL4L1 gene dose in relation to HIV infection, viral load, CD4
þ T-cell counts and rates of disease progression When the copy number of CCL3L1 and CCL4L1 was each dichotomized at the population-specific median for comparison of patient groups, possession of either gene at a copy number lower than the median was not associated with HIV-1 seropositivity (P40.50) ( Table 2 ). The copy number of CCL3L1 or CCL4L1, either as a continuous or as a categorical variable, was not associated with HIV-1 viral load or with CD4 þ T-cell count. Likewise, neither CCL3L1 nor CCL4L1 copy number was differentially distributed across the three distinct disease groups (controllers, intermediates and noncontrollers) 21 among the 227 HIV-1-seropositive patients (P40.50).
Joint analyses of CCL3L1 and CCL4L1 gene CNV in relation to HIV-1-related outcomes In further analyses of HIV-1 viral load and CD4 þ T-cell counts, the 207 HIV-1-infected, AIDS-free patients were divided into two subgroups. A subgroup (n ¼ 88) that displayed fewer copy numbers of both CCL3L1 and CCL4L1 than their respective population means was compared with the remainder as a reference group (n ¼ 119) for possible differences in repeated measure analyses of HIV-1 viral load or CD4 þ T-cell counts. Neither of these analyses demonstrated associations (P-values adjusted for age, gender and ethnicity ¼ 0.77 and 0.30, respectively). Likewise, no association was observed in similar analyses restricted to African Americans (n ¼ 54 in the group with low copy numbers and 94 in reference group; P-values ¼ 0.66 and 0.24). Another subgroup (n ¼ 103), redefined as having fewer copy numbers of joint CCL3L1 and CCL4L1 than their respective population means, was compared with the reference group (all others, n ¼ 104). The adjusted Pvalues for viral load and CD4 þ T-cell count were 0.84 and 0.14, respectively; corresponding P-values in tests on African Americans (54 subjects in subgroup and 94 in reference group) were 0.98 and 0.08. For tests based on a single visit (e.g., visit 1) (Supplementary Table) , the study population provided 80% power to detect differences (at a ¼ 0.05) that ranged from þ 0.37 to þ 0.46 log 10 for HIV-1 viral load and À89 to À111 cells for CD4 þ T-cell count. Differing from other CCL genes (e.g., CCL5 gene in an 8.9-kb region), the CCL3L1 and CCL4L1 loci are rather small in size (1.8-1.9 kb), so are the CCL3 and CCL4 loci (based on NCBI Entrez Gene at http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?db ¼ gene&cmd ¼ search&term).
Variable CCL3L1 and CCL4L1 copy number W Shao et al CCL3L1 and CCL4L1 gene dose in combination with CCR2-CCR5 haplotypes in relation to HIV-1-related outcomes In an earlier analytic scheme, 17 individuals with a favorable ligand gene dose (i.e., copy number higher than the population-specific median) combined with a favorable receptor genotype showed greater protection from HIV-1 and its consequences than those with a deleterious ligand gene dose (i.e., lower than the median copy number) combined with a deleterious receptor genotype. Here, CCL3L1 and CCL4L1 copy numbers could also be analyzed in conjunction with CCR2-CCR5 haplotypes. For improved statistical power, mixed models were applied to all subjects with data from eligible (treatment-free) visits. In the 207 chronically infected patients (CD4 þ T cell 4200/ml of blood), neither the extremes of viral load nor the extremes of CD4 þ Tcell count showed any appreciable overall association with particular receptor/ligand gene combinations. In alternative analyses (t-tests), slight trends in the predicted direction were noted at some but not all treatment-free visits (PX0.17). Further comparison of three patient groups defined as controllers, intermediates and noncontrollers 21 also led to negative findings (PX0.14).
Of note, the CCR2-CCR5 haplotype HHD found primarily in populations of African ancestry 20, 22, 23 was overrepresented (Pp0.002) in subjects with CCL3L1 and CCL4L1 copy numbers equal to or greater than the population-specific median numbers. However, HHD was not associated with HIV-1-related outcomes in this study population, 24 and the relationship did not confound the joint analyses of CCR2-CCR5 genotypes in combination with CCL3L1 and CCL4L1 copy numbers.
Quantification of serum MIP-1a (CCL3 þ CCL3L1) and MIP-1b (CCL4 þ CCL4L1) For 32 HIV-1-seronegative and 32 HIV-1-seropositive subjects (two visits per subject) with representative CCL3L1 and CCL4L1 gene copy numbers (Table 2) , serum MIP-1a and MIP-1b concentrations did not differ by gender, ethnicity or HIV-1 infection status (Table 3) . Although gene copy number was greater for CCL3L1 than CCL4L1 (Table 2) , median ratios of serum MIP-1a to MIP-1b were consistently less than 1.0 (Table 3) . Within the HIV-1-seropositive group, serum MIP-1a and MIP-1b concentrations did not correlate with HIV-1 viral load or CD4 þ T-cell counts (P40.50). The third ligand of CCR5, RANTES (CCL5), was present in serum at much higher concentrations (in the ng/ml range) when compared with serum MIP-1a and MIP-1b (both in the pg/ml range) ( Table 3 ). Serum CCL5 concentration was higher in HIV-1 seropositives than seronegatives (P ¼ 0.043 and 0.0001 by Mann-Whitney U-test, for visit 1 and visit 2, respectively), although correlation between serum CCL5 and HIV-1 viral load was weak (Spearman ro0.30, P40.05 for measures averaged for the two visits) (data not shown).
Discussion
Host genetic variations are increasingly recognized as partly accounting for individual and population 31 whose products are known to block or interfere with HIV-1 binding to CCR5 (the major coreceptor for primary viral isolates). [32] [33] [34] [35] Overall, these studies indicate that CCL3L1
(a non-allelic variant of CCL3) is probably the most potent ligand for CCR5 and that production of CCL3L1 transcripts and protein (MIP-1a) correlates positively with CCL3L1 gene copy number. 14, 17 Unlike many other CNVs found in about 12% of the human genome, 36 CNVs for CCL3L1 and CCL4L1 can be readily assessed for their relation to protein expression. However, apart from confirming the variability and comparable median numbers of CCL3L1 and CCL4L1 copies in the two ethnic groups represented, our work did not detect any relationship of CCL3L1 and CCL4L1 CNVs to quantifiable differences in the systemic circulation of MIP-1a and MIP-1b as measured by serum concentration. The enzyme-linked immunosorbent assay (ELISA) detected overall MIP-1a without distinguishing CCL3L1 from CCL3 (the two mature products differ by three amino-acid residues), but the correlation analysis was not compromised as CCL3 occurs as a single-copy gene uniformly in all subjects. Therefore, differences in serum MIP-1a levels are more likely attributable to the variability in CCL3L1 copy number than to expression of the single-copy CCL3 gene. 14, 17 The same inference would apply to MIP-1b, which corresponds to CCL4 plus CCL4L1 (their mature peptides are identical in amino-acid sequence).
The HIV-1 serostatus and key outcome measures of HIV-1 disease control were not associated with CCL3L1 or CCL4L1 copy numbers, either alone (as continuous or categorical variables) or in combination with the CCR2-CCR5 haplotypes. These findings were somewhat consistent with that of an earlier study based on 150 subjects.
14 Additional convincing evidence against a prominent association of these two chemokine gene products (MIP-1a and MIP-1b) with HIV-1 infection or disease outcomes in our study population came from the quantification of all three principal chemokine ligands of CCR5. Serum concentrations of MIP-1a and MIP-1b showed inter-individual differences, but they were too far lower than that of CCL5 (RANTES) to be biologically dominant. Even if CCL3L1 (detected as MIP-1a in ELISA assays) is considered the most potent ligand for CCR5, with 10 times the affinity of other CCR5 ligands (e.g., CCL5), 14 the amounts of serum MIP-1a (in the pg/ml range) relative to amounts of CCL5 (in the ng/ml range) 
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African Americans Others Figure 2 Distribution of CCL3L1 and CCL4L1 gene copy numbers in the study population (n ¼ 411) stratified by ethnicity (about 70% are African Americans). Overall, variability is less in CCL4L1 than CCL3L1 gene copy numbers. Median copy number is greater in African Americans (four CCL3L1 and three CCL4L1 per individual) than in those loosely defined others (three CCL3L1 and two CCL4L1 per individual). As quantified in real-time 5 0 exonuclease (TaqMan) assays normalized against the hemoglobin, beta gene (HBB) in each subject (see text and Table 1 ). Data stratified by race are shown in Figure 2 . IQR: interquartile range (the 25-75th percentile). b Twenty of these patients had advanced infection (CD4 + T-cells o200/ml of blood) at treatment-free visits; they were not used for analyses of HIV-1 viral load or CD4 + T-cell counts.
Variable CCL3L1 and CCL4L1 copy number W Shao et al seem trivial from the functional perspective. To date, neither MIP-1a nor MIP-1b serum concentration has ever been correlated with HIV-1-related outcomes, 37 whereas circulating CCL5 (RANTES), especially as measured in plasma depleted of CCL5-rich platelets, 38, 39 may be a useful biomarker in HIV-1 patients. 37, 40, 41 The elevated concentrations of serum CCL5 in our HIV-1-seropositive patients were quite consistent with all earlier observations. 37, 40, 41 Recent array-based work has also corroborated the upregulation of CCL5 (RANTES) transcription by HIV-1 infection, 42 suggesting that CCL5 is likely to be a dominant chemokine factor in HIV-1 infection.
Apart from sample size (statistical power), the mostly female (B70%) and African American (B70%) adolescents from the REACH (Reaching for Excellence in Adolescent Care and Health) project differ in age, racial/ethnic background, sex ratio, and follow-up intervals from other populations with defined CCL3L1 CNVs. 14, 17, 43 Accordingly, findings from this cohort may not always be generalizable. Nonetheless, our study was expected to have adequate (80%) statistical power to detect modest differences in HIV-1 viral load and CD4 þ T-cell counts, before and after stratification by race (Supplementary Table) . Smaller differences would have been more difficult to detect, but trends toward the predicted relationships of the reported magnitude 17 should have been observable. Overall, CCL3L1 and CCL4L1 CNVs or their combination failed to exert major impact on early outcomes after HIV-1 infection in this adolescent population.
Multiple CCL3L1 and CCL4L1 copies may have resulted from segmental gene duplication, most likely through unequal crossing over. In this duplication process, CCL3L1 and CCL4L1 are often preserved in a single unit. [14] [15] [16] However, in our study population, the copy numbers of CCL3L1 and CCL4L1 showed only a modest linear correlation, suggesting that these two genes are not always duplicated simultaneously (i.e., at a 1:1 ratio). Such discordance in CCL3L1 and CCL4L1 gene copy numbers supports the existence of a second duplication unit.
14 Our analyses of chimpanzee DNA further imply that humans may have preferentially lost the extra copies of CCL3L1, as measurement of MIP-1a concentration in human serum suggested that additional copies do not seem to provide any clear advantage for systemic production. Close similarity (over 95% sequence identity at both the genomic and the mRNA levels) between CCL3 and CCL3L1 16 reinforces the redundancy of these loci. The regulatory elements for CCL3 and CCL3L1 do not seem to operate in a similar way; rather, CCL3 mRNA transcripts accumulate much faster than does CCL3L1 mRNA in mitogen-stimulated peripheral blood mononuclear cells derived from healthy subjects (mean CCL3L1 copy number ¼ 2). 44 Overall, absence of CCL3L1 in some healthy (HIV-1-seronegative) individuals here and elsewhere (in Australians) 43 suggests that this locus may be expendable under certain conditions. On the other hand, because CNVs may be more important in some cell lineages than others, CCL3L1 gene copy and function in humans merit additional study in the setting of HIV-1 infection. They should prove even more informative if monoclonal antibodies can be produced to distinguish CCL3 from CCL3L1 and their full-length products from those slightly truncated at the N-terminus by CD26 and quiescent cell proline dipeptidase. 45, 46 Subjects and methods
Study population and outcome measurements
All human subjects came from the REACH Study of the Adolescent Medicine and HIV/AIDS Research Network, which recruited HIV-1-infected or high-risk uninfected adolescents (mostly females and African Americans) at 15 locations in 13 US cities. The characteristics of this cohort have been described previously. 47, 48 Between 1996 and 2000, data were collected at quarterly intervals for as many as 550 subjects, of whom 530 had a sample suitable for DNA extraction. Subjects selected for this study included 184 HIV-1 seronegatives (population controls) and 227 HIV-1 seropositives (161 African Americans and 66 others) with known history of exposure to antiretroviral therapy (ART) and up to four measurements of HIV-1 viral load (RNA copies per ml) in plasma and corresponding CD4 þ T-cell counts during ART-free þ T-cell counts at multiple ART-free intervals allowed the classification of three distinct disease groups (37 controllers, 134 intermediates and 56 noncontrollers) among HIV-1 seropositives. 24 Several immunogenetic effects established in other studies of HIV-1 infection have been corroborated in this cohort. 21, 24 Quantification of CCL3L1 and CCL4L1 gene copy number Several 5 0 nuclease (TaqMan) assays were designed to quantify the copy numbers of CCL3L1, CCL3, CCL4L1 and CCL4, when the single-copy gene hemoglobin, beta (HBB), served as the internal control. TaqMan assay for CCL3L1 was similar to that used earlier, 17 with minor modifications. This assay determined human CCL3L1 gene dose by distinguishing CCL3L1 from CCL3 (Table 1) . TaqMan assays for CCL3, CCL4 and CCL4L1 were new from Applied Biosystems (Assay-by-Design) (Applied Biosystems, Foster City, CA, USA), and specificity was confirmed by bioinformatics. Real-time PCR was done using the AB 7500 Fast System (Applied Biosystems Inc.), with the following universal cycling conditions: 2 min at 501C, 10 min at 951C, and 40 cycles of 15 s at 921C and 1 min at 601C. All the samples were tested in duplicate. For each of the four target loci, gene copy number in each individual sample was determined by the relative quantification program (Applied Biosystems). Calculations were based on the estimates of template quantities, after comparing the threshold cycle numbers at which positive (over background) fluorescence was detected. 49, 50 The housekeeping gene HBB, which is present at two copies per diploid genome, served to standardize the chemokine gene copy number counts: the copy number of CCL3L1, CCL3, CCL4L1 and CCL4 each was taken as two times the ratio of its respective starting template quantity to that of HBB. To gain additional evolutionary perspective, CCL3 and CCL3L1 TaqMan assays were further applied to DNA from six chimpanzees (Pan troglodytes) (courtesy of Dr Patricia N Fultz, Department of Microbiology, University of Alabama at Birmingham).
Chemokine receptor gene (CCR2 and CCR5) variants Nine major haplotypes at the CCR2 and CCR5 loci had been classified in the study population based on eight common SNPs and the 32-bp deletion in CCR5 genes. 21, 24 This new classification scheme also captured other variants (e.g., the 59029G SNP and the P1 haplotype) that have been prominently associated with HIV-1 disease progression. 51, 52 Because the favorable and unfavorable haplotypes and their combinations as defined elsewhere 20, 23, 24, 53 probably act in concert with CCL3L1 and CCL4L1 copy numbers, 17 combinations of CCR2-CCR5 haplotypes and CCL3L1/CCL4L1 gene copy numbers were further evaluated for association with HIV-1-related outcome measures.
MIP-1a (CCL3 þ CCL3L1), MIP-1b (CCL4 þ CCL4L1) and CCL5 (RANTES) concentrations in serum Serum MIP-1a and MIP-1b concentrations were analyzed by a multiplex SearchLight assay (Pierce Biotechnology Inc., Rockford, IL, USA), which is similar to sandwich ELISA, with improved sensitivity and reduced intra-and inter-assay variability. The lower detection limit for SearchLight assay was 3.0 and 0.8 pg/ml for MIP-1a and MIP-1b, respectively. CCL5 ELISA was done using a commercial sandwich ELISA kit (R&D Systems, Minneapolis, MN, USA), as described elsewhere. 54 The lower detection limit for CCL5 was 2.0 pg/ml.
Statistical analyses
Standard procedures in the SAS (Statistical Analysis Software) version 9.1 (SAS Institute Inc., Cary, NC, USA) were used for descriptive and comparative statistics. Briefly, the relationship between CCL3L1 and CCL4L1 copy numbers was determined using the Pearson correlation coefficient. Linear regression models were used to test associations of genetic factors (CCL3L1 and CCL4L1 gene dose and their combination with CCR2-CCR5 genotypes) with cell-free HIV-1 viral load (RNA copies per ml of plasma) and CD4 þ T-cell counts (for visits without ART). Differences in CCL3L1 and CCL4L1 gene copy numbers between HIV-1 seronegative and seropositive were assessed by w 2 -tests or logistic regression, with adjustment for other host factors like age, gender, ethnicity, sexual behavior and other sexually transmitted infections (chlamydia, gonorrhea and human herpes virus type 2). 55, 56 Moreover, analytic routines (mixed models) were used to stabilize the repeated measure analysis of outcomes (viral load and CD4 þ Tcell counts).
